bevacizumab,panitumumab
roche,takeda,amgen
['biomarker', ' bev ', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
 biomarker study &amp; updated os data of the phase iii paradigm study #asco23 802 pts, 91% with ctdna left #mcrc with mss &amp; ras/braf wt -&gt; os longer with pan #mcrc with msi &amp; ras/braf mut -&gt; os tended longer with bev no surprises.... 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology